Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials

European Respiratory Review

Volumn 25, Issue 139, 2016, Pages 29-35

  Moodley, Riya ^a   Godec, Thomas R ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

BANGLADESH; CLINICAL EVALUATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MULTIDRUG RESISTANT TUBERCULOSIS; NEPHROTOXICITY; PANCREAS DISEASE; PANCREATIC TOXICITY; PANCREATIC TOXICTY; PATIENT CARE; PATIENT MONITORING; POPULATION STRUCTURE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE; SHORT COURSE THERAPY; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; LUNG; METHODOLOGY; MICROBIOLOGY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; TIME FACTOR; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; LUNG; MYCOBACTERIUM TUBERCULOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 85015466776     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0080-2015     Document Type: Review

References (21)

1. World Health Organization. Global Tuberculosis Report 2015. Geneva, World Health Organization, 2015.
2. World Health Organization. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis: 2011 Update. Geneva, World Health Organization, 2011.
3. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516–528.
4. Van Deun A, Maug AKJ, Salim MAH, et al. Short, highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684–692.
5. Diel R, Nienhaus A, Lampenius N, et al. Cost of multi drug resistance tuberculosis in Germany. Respir Med 2014; 108: 1677–1687.
6. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014; 43: 554–565.
7. Aung KJM, Van Deun A, Declercq E, et al. Successful “9-month Bangladesh regimen” for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180–1187.
8. Kuaban C, Noeske J, Rieder HL, et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 517–524.
9. Piubello A, Harouna SH, Souleymane MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188–1194.
10. Trébucq A, Schwoebel V, Kuaban C, et al. Expanding shortened MDR-TB treatment: the West African experience. Int J Tuberc Lung Dis 2014; 18: Suppl. 1, S15.
11. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
12. Nunn AJ, Rusen ID, Van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials 2014; 15: 353.
13. National Institute of Allergy and Infectious Diseases. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. www.niaid.nih.gov/labsandresources/resources/daidsclinrsrch/documents/daidsaegra dingtable.pdf Date last updated: December, 2004.
14. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10: 605–612.
15. Food and Drug Administration. Determination That TEQLUIN (Gatifloxacin) Was Withdrawn From Sale for Reasons of Safety or Effectiveness. www.fda.gov/OHRMS/DOCKETS/98fr/cd07129-n.pdf Date last updated: September 9, 2008.
16. Cox E, Laessig K. FDA approval of bedaquiline – the benefit–risk balance for drug-resistant tuberculosis. N Engl J Med 2014; 371: 689–691.
17. Mahajan R. Bedaquiline: first FDA-approved drug in 40 years. Int J Appl Basic Med Res 2013; 3: 1–2.
18. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289–292.
19. World Health Organization. The Use of Bedaquiline in the Treatment of Multidrug-resistant Tuberculosis: Interim Policy Guidance. http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf Date last accessed: October 18, 2015. Date last updated: June 2013.
20. Nunn A, Phillips P, Mitchison D. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis 2010; 14: 241–242.
21. World Health Organization. Resistance to Pyrazinamide and Fluoroquinolones: Results from a Multi-country Surveillance Project. Proceedings of the 45th Union World Conference on Lung Health; October 28–November 1, 2014; Barcelona, Spain. www.who.int/tb/advisory_bodies/impact_measurement_taskforce/meetings/barcelona2014_ zignol.pdf Date last accessed: October 22, 2015. Date last updated: October 2014.